Agenus (AGEN) Tops Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. NVDA
2. DPZ
3. DRS
4. GS
5. BAC
6. UNH
7. ORCL
8. AVAV
9. ACI
10. META

Go back to Agenus (AGEN) Tops Q2 EPS by 6c

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report

August 9, 2022 8:01 AM EDT

Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC)Agenus expects to present additional botensilimab expansion cohort data at upcoming conferences in 2022First patient dosed in Phase 1 study of AGEN1571 (anti-ILT2) in advanced solid tumors

LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today provided a corporate update and reported financial results for... More